Vymedic Founder Cynthia Winning on Antiviral Solutions

Vymedic is a biotech startup founded on the discovery that certain amino acids exhibit antiviral and therapeutic properties. The discovery of these properties led to the development of a new amino acid metabolic technology that delivers safe, transformative products to preserve health. The first of which is the first known natural broad-spectrum antiviral.

My sister fell ill from an autoimmune disorder that was destroying her organs. There is no cure. She was given organ transplant drugs to suppress her immune system and stop the attacks. But, without an immune system, she was told a common cold could kill her because there are no antivirals to stop colds, flu, or common viruses. She was also told to isolate from November to April to avoid viruses. As a college administrator, she had to give up her career. So as a marketing and new product development executive, I was motivated to find a cure. At that time, my company was being acquired and I had the choice to move to Philadelphia or take a golden parachute. I took the package and began looking for an antiviral to help her reclaim her life.

As a successful corporate new product development and marketing executive in fortune 100 fintech and telecom companies, I’m experienced in understanding complex technologies and turning them into successful, convenient, and valued consumer products. Each of these roles supported start-up new business enterprises in existing corporations. In Citigroup, as a Vice President and Director of Marketing, I was on the start-up team for Citicorp Retail Services, now called Citi Retail Services. This was the bank’s first foray into private label retail credit. In Telecom, I was brought on board as Group Vice President of Marketing and Programming to lead the 5th largest MSO from a low-tech utility to a successful high-tech competitive communications company. As a result, I understand the rigors and disciplines involved in developing successful start-ups and turnarounds. I’m trained and experienced in driving the key metrics of success including profitability and shareholder value. I’ve led many high performing teams to deliver this success.

I see the immune support and health management industry as quite robust and I believe the industry will continue to experience exceptional growth. This is reflected in IBS/World research which forecasts $10.5 billion in cough and cold medicine sales in 2020 and its reporting that demand has never been higher for immune support. Current global health threats have also increased consumer desire for safe and effective options to support immune health.

Once our antiviral product Vymune was proven safe and effective through our in vitro and human clinical trial research, it was time to go to market. I joined an accelerator called Co-Founders Lab to learn how to pitch to investors. Steve Lehman owned the accelerator and he took an interest in Vymune. Steve is now our Executive Chairman and a board member. Mr. Lehman has an extensive financial and business background. Steve has been CEO of both Nasdaq and NYSE companies. Mr. Lehman is a successful entrepreneur and investor and was a first-round investor in Mark Cuban’s Broadcast.com. He was an Advisory Board member of DocuSign and is a current Board Member of Global Mentor Networks, founded by Keith Krach, Under Secretary of The US Department of State for Economic Growth. He has added much value to Vymedic’s development and evolution.

When it was time to add a corporate attorney, Dave Bartlett was highly recommended by our patent law firm Merchant & Gould. David E. Bartlett, Attorney-at-Law, represents companies at start-up, development, growth stages, mergers, and acquisitions. Mr. Bartlett has co-founded several high-tech companies and was previously a partner at Cooley Godward LLP, a Silicon Valley Law Firm. Mr. Bartlett has authored books and articles and is an elected member of the American Law Institute. Mr. Bartlett is also a Vymedic, Inc. board member.

Lee Peterson, our CFO, has been Vymedic’s corporate accountant since its inception. Lee is a CPA. He provides income tax, accounting, and financial consulting services. He was a tax manager for a top multi-national CPA firm and holds a Bachelor of Science Degree in Economics from California State Polytechnic University.

Gerald Mills is a Board Member. He spent 28 years in various senior human resource positions at Owens Corning Corporation, including Director of Compensation and Benefits and Vice President of Human Resources for the global composites division which was a $1.5 B business. In retirement, Jerry was recruited by a CEO for two turnaround businesses in extreme financial distress, Eagle Picher Industries, and Remy International. Eagle Picher was improved and sold. Remy was completely turned around and taken public on NASDAQ in 2012. In both cases, he addressed issues encountered as if they were entrepreneurial start-ups. In addition to his Board work, Mr. Mills will oversee our corporate recruiting and benefits.  

We have three competitors. Two are competitors in Immune Support. They are Airborne and Emergen-C. Our Drug competitor is Tamiflu, a single spectrum drug for use in influenza.

Research has shown that both Airborne and Emergen-C are immunosuppressants. See US patent: US5626883Paul. It has been shown that products supplying 1G ascorbic acid cause transitory suppression of the immune system for up to 4 hours. Anyone attempting to stop a pathogen by taking these products risks causing the pathogen to multiply by a factor of 64 during the transitory suppression period.

Vymune’s ascorbate formulation does not cause transitory suppression.
In the case of the drug Tamiflu, it has been shown that Tamiflu can reduce a 7 day flu infection by less than one day (6.5 hours). Additionally, Tamiflu has been rated a class C drug, dangerous for pregnant women and children, as it suppresses MMP-9, which is responsible for fetal tissue growth.

Vymune shows a safe MMP-9 expression and in our many in vitro studies using Tamiflu, Vymune has outperformed this drug in every study. Additionally, due to its mechanism of action, Vymune inhibits flu in less than 48 hours.

The discovery of the therapeutic value of amino acids is a true medical breakthrough in the advancement of safe, effective, new treatments. Vymedic is the leader in Amino Acid Technology and as such only Vymedic can deliver these novel patented products.

Vymedic will deliver important, novel, patented products to support medical healing. Additionally, with 24 domestic and global patents, which include North America, the EU, Great Britain, and Asia, it is likely that we may enter into a relationship in the future with a global pharmaceutical or consumer products company. Our future goals include the launch of up to three additional amino acid-based products that are in development and target various medical conditions.